|Posted on March 17, 2021 at 7:15 PM|
The pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, aiming to disrupt a market led by Allergan and Novartis.
Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche.
But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Al...Read Full Post »
Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease
|Posted on January 24, 2021 at 6:55 AM|
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.
The double-masked, single-center, parallel-group run-in cohort enrolled 23 patients: 12 patients were randomized to receive 0.25% reproxalap ophthalmic solution and 11 patients were randomized to receive veh...Read Full Post »
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
|Posted on January 10, 2021 at 7:55 AM|
- Ocular Pain, a $10+ billion global market, with significant unmet medical need
- License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies
Irvine, Calif., Paris, Hong Kong, Jan. 7, 2021 /PRNewswire/ — IACTA Pharmaceuticals, Inc. (“IACTA" and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with ...Read Full Post »
|Posted on November 28, 2020 at 7:00 AM|
SilkTech Biopharmaceuticals has completed enrollment in a phase 2b clinical trial of SDP-4, its eye drop formulation for the treatment of the signs and symptoms of dry eye disease, according to a press release.
The randomized, double-masked, vehicle-controlled, multicenter trial is evaluating the safety and efficacy of SDP-4 at 0.1%, 1% and 3% concentrations in 305 patients at 25 U.S. sites.
SDP-4, a biotherapeutic naturally derive...Read Full Post »
|Posted on November 16, 2020 at 8:20 AM|
A phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of dry eye disease has been initiated, according to a press release from Aerie Pharmaceuticals.
COMET-1 is a randomized, double-masked, vehicle-controlled trial investigating the safety and efficacy of AR-15512, a TRPM8 agonist. The trial aims to enroll about 360 patients who will receive AR-15512 0.0014%, AR-15512 0.003% or AR-15512 vehicle, one drop twice daily in e...Read Full Post »